A Phase 1, Open-label, Dose Finding Study of CC-90009 in Subjects With Relapsed, Refractory Acute Myeloid Leukemia
Phase of Trial: Phase I
Latest Information Update: 06 Sep 2017
At a glance
- Drugs CC 90009 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; First in man
- Sponsors Celgene Corporation
- 29 Aug 2017 Planned End Date changed from 1 Jun 2021 to 21 Jun 2021.
- 29 Aug 2017 Planned primary completion date changed from 1 Aug 2019 to 5 Aug 2019.
- 11 Oct 2016 Status changed from not yet recruiting to recruiting.